Isotretinoin-basal cell carcinoma prevention trial. Design, recruitment results, and baseline characteristics of the trial participants. The ISO-BCC Study Group.

@article{Tangrea1990IsotretinoinbasalCC,
  title={Isotretinoin-basal cell carcinoma prevention trial. Design, recruitment results, and baseline characteristics of the trial participants. The ISO-BCC Study Group.},
  author={Joseph A. Tangrea and Brenda Kay Edwards and Anne Marcia Hartman and Philip R. Taylor and Gary L. Peck and Stuart J. Salasche and Pradeep Aravindan Menon and George B. Winton and R Mellette and Marshall A Guill},
  journal={Controlled clinical trials},
  year={1990},
  volume={11 6},
  pages={433-50}
}
The Isotretinoin-Basal Cell Carcinoma Prevention Trial (ISO-BCC Study) is a double-masked, randomized, placebo controlled, multicenter clinical trial. It is the first intramural cancer chemoprevention trial sponsored by the Division of Cancer Prevention and Control of the National Cancer Institute. This trial was designed to evaluate the effectiveness of chronic administration of low dosage levels (10 mg) of a synthetic retinoid, isotretinoin, in reducing the incidence of basal cell carcinoma… CONTINUE READING

Similar Papers

Loading similar papers…